Status:
COMPLETED
Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19 (TEDHICOV)
Lead Sponsor:
Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud
Conditions:
Covid19
SARS-CoV Infection
Eligibility:
All Genders
18+ years
Brief Summary
Although several therapeutic agents have been suggested for the treatment of the disease caused by the Coronavirus of the year 2019 (COVID-19), no antiviral has yet demonstrated consistent efficacy. ...
Detailed Description
All hospitalized patients with COVID-19 from March 2020 to May 30, 2020 at the "Hospital Nacional Carlos Alberto Seguín Escobedo (CASE)-EsSalud" (Arequipa, Peru) with a PCR-confirmed diagnosis of SARS...
Eligibility Criteria
Inclusion
- Hospitalized adults over 18 years of age
- Positive molecular test for SARS-CoV-2
- Computed tomography (TC scan) compatible with "COVID pneumonia" and / or in need of supplemental oxygen
- Therapy with Tenofovir-DF (TDF) or Hydroxychloroquine (HCQ) at least 3 days
- Signed informed consent
Exclusion
- Negative molecular test for SARS-CoV-2
- No need for hospitalization
- Negative CT scan for "COVID pneumonia" and / or no supplemental oxygen requirement for COVID-19
- Had not received either HCQ or TDF, or both drugs at the same time, or had received HCQ or TDF for two days or less
- No signed informed consent
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 15 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04812496
Start Date
March 1 2020
End Date
January 15 2021
Last Update
March 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Nacional CASE - EsSalud
Arequipa, Peru, 04001